Stefan Creadore

Dr. Stefan Creadore

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in Protein Science
Verified
Journal Article
Closed access
PDF file
ADApril L. Darling
April L. Darling
JDJan Dahrendorff
Jan Dahrendorff
Stefan CreadoreStefan Creadore
Stefan Creadore
CDChad A. Dickey
Chad A. Dickey
LBLaura J. Blair
Laura J. Blair
Vladimir N. UverskyVladimir N. Uversky
Vladimir N. Uversky

1 June 2021 in Translational Oncology
Verified
Journal Article
Open access
MHMonica Hsiang
Monica Hsiang
BCBoris I. Chobrutskiy
Boris I. Chobrutskiy
MDMichael Diaz
Michael Diaz
THTaha I. Huda
Taha I. Huda
Stefan CreadoreStefan Creadore
Stefan Creadore
GBGeorge Blanck
George Blanck
Uterine cancer has been associated with a T-cell immune response that leads to increased survival. Therefore, we used several bioinformatics approaches to explore specific interactions between T-cell receptor (TCR) and tumor mutant peptide sequences. Using endometrioid uterine cancer exome files from the The Cancer Genome Atlas database, we obtained tumor resident V-J recombinations for the T-Cell Receptor alpha gene (TRA). The charged-based, chemical complementarity for each patient's LRP2 or TTN mutant amino acids (AAs) and the recovered, TRA complementarity determining region-3 (CDR3) sequences was calculated, allowing a division of patients into complementary and noncomplementary groups. Complementary groups with TTN mutants had increased disease-free survival and increased expression of complement genes. Furthermore, the survival distinction based on CDR3-mutant peptide complementarity was independent of programmatically assessed HLA class II binding and was not observable based on the CDR3 AA chemical features alone. The above approach provides a potential, highly efficient method for identifying TCR targets in uterine cancer and may aid in the development of novel prognostic tools.

8 July 2021 in Genes
Verified
Journal Article
Open access
PDF file
XLXenia Latypova
Xenia Latypova
Stefan CreadoreStefan Creadore
Stefan Creadore
NDNoémi Dahan-Oliel
Noémi Dahan-Oliel
AGAnxhela Gustafson
Anxhela Gustafson
SHSteven W Hwang
Steven W Hwang
KDKlaus DIETERICH
Klaus DIETERICH
Arthrogryposis multiplex congenita (AMC) describes a group of conditions characterized by the presence of non-progressive congenital contractures in multiple body areas. Scoliosis, defined as a coronal plane spine curvature of ≥10 degrees as measured radiographically, has been reported to occur in approximately 20% of children with AMC. To identify genes that are associated with both scoliosis as a clinical outcome and AMC, we first queried the DECIPHER database for copy number variations (CNVs). Upon query, we identified only two patients with both AMC and scoliosis (AMC-SC). The first patient contained CNVs in three genes (FBN2, MGF10, and PITX1), while the second case had a CNV in ZC4H2. Looking into small variants, using a combination of Human Phenotype Ontogeny and literature searching, 908 genes linked with scoliosis and 444 genes linked with AMC were identified. From these lists, 227 genes were associated with AMC-SC. Ingenuity Pathway Analysis (IPA) was performed on the final gene list to gain insight into the functional interactions of genes and various categories. To summarize, this group of genes encompasses a diverse group of cellular functions including transcription regulation, transmembrane receptor, growth factor, and ion channels. These results provide a focal point for further research using genomics and animal models to facilitate the identification of prognostic factors and therapeutic targets for AMC.